Journal of Pharmaceutical Care & Health Systems
Open Access
ISSN: 2376-0419
ISSN: 2376-0419
Ankit K. Rochani and Gagan Kaushal
Thomas Jefferson University, USA
Scientific Tracks Abstracts: J Pharma Care Health Sys
Nanomedicine has been playing a critical role in the shaping the formulation realm of pharmaceutical companies. Looking at the significance of nanoformulations in drug delivery, various synthetic and natural biomaterials are being explored in their native or composite states to create newer and better nano drug delivery vectors. Over the years of experimentation and developing polymeric nanoparticles, we have realized that personalized nano drug delivery may help in overcoming biosafety and hypersensitivity of existing drug delivery techniques. Personalized nano drug delivery is an adaptation of personalized anticancer therapy. The concept is based on the use of the body�??s own biomaterial for developing nanoformulations in order to bypass the biosafety issues revolving around the use of synthetic or semi-synthetic biomaterial as pharmaceutical excipients. In order to test our hypothesis, we developed formulations with albumin. Albumin protein covers around 60% of human serum proteins and serves as a natural drug carrier in the human body. Taking advantage of this natural phenomenon we have developed Hsp90 inhibitor loaded albumin nanoparticles. Our study shows that the synthesized drug loaded albumin nanoparticles were found to be effective (under in-vitro condition) against both pancreatic (MiaPaCa-2) and breast cancer (MCF7) cell lines. Our studies indicate that our nanomedicine platform, which consists of both synthetic and natural (protein based) polymers that can play a significant role in the delivery of Hsp90 targeted anticancer drugs for next-generation anticancer therapy. Looking at the significance of albumin in personalized nano drug delivery, we also discovered that albumin hydrogel can also be explored as a transdermal drug delivery vehicle for the anticancer drugs. Our studies with albumin clearly show that it can work as a next-generation biomaterial for personalized nano drug delivery vector for new drug molecules.
Rochani is a pharmaceutical chemist with Ph.D. in Bio Nano Fusion Science. He has extensive experience in translation research and worked with various biomaterials for developing Nano drug delivery vectors. Over the years of work in the field of (Hsp90 targeted) personalized therapy for cancer and infectious diseases. He has been developing intriguing nanomedicine concepts for cancer therapy that laid the foundation for the concept of personalized nano drug delivery. He has developed various Nanoconstructs like nanoparticles, nanofibers and recently, he has developed a protein-based hydrogel system for personalized nano transdermal drug delivery applications. His, research interests include drug delivery, nanomedicine, proteomics, metabolomics, computational chemistry, and repositional based approaches for drug design and development.
E-mail: ankit.rochani@jefferson.edu